NCI Drug Dictionary
The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
A recombinant therapeutic agent which is chemically identical to or similar to endogenous human GM-CSF. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonyms:||23-L-leucine colony-stimulating factor 2 |
granulocyte macrophage colony-stimulating factor
|US brand names:||Leukine |